

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

STEFAN KNACKMUSS ET AL

U.S. Serial No. 10/574,961

Filed: July 5, 2006



Group Art Unit 1648

Examiner: A. Boesen

SINGLE CHAIN ANTIBODIES AGAINST 37 KDA/67 KDA LAMININ RECEPTOR AS
TOOLS FOR THE DIAGNOSIS AND THERAPY OF PRION DISEASES AND CANCER,
PRODUCTION AND USE THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Transmitted herewith is an amendment / ~~a response~~ in the above-
identified application.

 X No additional fee is required.
 An additional fee is required as calculated below -

	Claims Remaining After Amendment	Highest No. Previously Paid For	Present Extra	Small Entity		Other Than A Small Entity	
				Addnl. Rate	Fee	Addnl. Rate	Fee
Total	_____	Minus * _____	_____	x \$ 25	\$ _____	x\$ 50	\$ _____
Indep	_____	Minus * _____	_____	x \$105	\$ _____	x\$210	\$ _____
First Presentation of Mul Dep Claim.....				x \$185	\$ _____	x\$370	\$ _____
Total Additional Fee.....				\$ _____		\$ _____	

* The "Highest Number Previously Paid For" (Total or Independent) is the highest number of claims filed originally or highest number found from equivalent box of a prior amendment.

 This response is being filed within the period for response.

 X Applicant(s) hereby petition for an extension from the date
of the Examiner's Action as follows:

 X First-Month Extension..... \$ 60.00 / \$ ~~120.00~~
 Second-Month Extension..... \$ 230.00 / \$ 460.00
 Third-Month Extension..... \$ 525.00 / \$1050.00

 X Small entity status of this application has been established.

A Check in the amount of \$ 60.00 is attached hereto. The
Commissioner is hereby authorized to charge any additional fees which may
be required, or credit any overpayment to Deposit Account No. 02-3690 of
the undersigned attorney. A duplicate copy of this sheet is enclosed.

06/05/2008 AUCNDAF1 00000001 10574961

Respectfully submitted,

60.00 00

Date: June 4, 2008
(703) 684-6885

By

Mary J. Breiner
Mary J. Breiner, Reg. No. 33,161
Attorney of Record

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

STEFAN KNACKMUSS ET AL

U.S. Serial No. 10/574,961

Filed: July 5, 2006



Group Art Unit 1648

Examiner: A. Boesen

SINGLE CHAIN ANTIBODIES AGAINST 37 KDA/67 KDA LAMININ RECEPTOR AS
TOOLS FOR THE DIAGNOSIS AND THERAPY OF PRION DISEASES AND CANCER,
PRODUCTION AND USE THEREOF

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

Transmitted herewith is an amendment / ~~a response~~ in the above-identified application.

 X No additional fee is required.
 An additional fee is required as calculated below -

	Claims Remaining After Amendment	Highest No. Previously Paid For	Present Extra	Small Entity Addnl. Rate	Fee	Other Than A Small Entity Addnl. Rate	Fee
Total	<u> </u>	Minus * <u> </u>	<u> </u>	x \$ 25	\$ <u> </u>	x\$ 50	\$ <u> </u>
Indep	<u> </u>	Minus * <u> </u>	<u> </u>	x \$105	\$ <u> </u>	x\$210	\$ <u> </u>
First Presentation of Mul Dep Claim.....				x \$185	\$ <u> </u>	x\$370	\$ <u> </u>
Total Additional Fee.....				\$ <u> </u>		\$ <u> </u>	

* The "Highest Number Previously Paid For" (Total or Independent) is the highest number of claims filed originally or highest number found from equivalent box of a prior amendment.

 This response is being filed within the period for response.

 X Applicant(s) hereby petition for an extension from the date of the Examiner's Action as follows:

 X First-Month Extension..... \$ 60.00 / \$ ~~120.00~~
 Second-Month Extension..... \$ 230.00 / \$ 460.00
 Third-Month Extension..... \$ 525.00 / \$1050.00

 X Small entity status of this application has been established.

A Check in the amount of \$ 60.00 is attached hereto. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-3690 of the undersigned attorney. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

By

Mary J. Breiner, Reg. No. 33,161
Attorney of Record

Date: June 4, 2008
(703) 684-6885

COPY